52670 Federal Register / Vol. 76, No. 163 / Tuesday, August 23, 2011 / Notices 

Dated: August 17, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–21487 Filed 8–22–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

2011 Technology Transfer Summit 

North America Conference 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice of Conference. 

SUMMARY: The NIH Office of Technology 

Transfer extends invitations to attend 

the 2011 Technology Transfer Summit 

North America Conference. 

DATES: October 3–4, 2011. 

ADDRESSES: NIH campus, 9000 

Rockville Pike, Bethesda MD, NIH 

Clinical Center (Building 10), Masur 

Auditorium. 

SUPPLEMENTARY INFORMATION: The NIH 

campus in Bethesda, MD will be the site 

for the 2011 Tech Transfer Summit 

North America (TTSNA), the leading 

early-stage biotech partnering, licensing, 

venture and innovation platform, cohosted and co-sponsored by the NIH 

Office of Technology Transfer, TTS Ltd. 

and regional host partners such as BIO 

Maryland. 

TTSNA is one of a series of summits 

held within the Global Tech Transfer 

Initiative and is designed specifically to 

put innovators, early-stage SMEs and 

technology managers from leading 

universities and research institutes 

together with biotech & pharma 

licensing & business development 

executives, VCs, serial entrepreneurs, 

and leading IP specialists for interactive 

sessions relating to partnering, licensing 

& business development. 

Conference speakers for the 2011 

include: 

—Kathy Hudson, Deputy Director, 

National Institutes of Health (NIH) 

—James C. Greenwood, President & 

CEO, BIO 

—Shiv Krishnan, Director, Scouting & 

Partnering, Sanofi, USA 

—Sanjeev Munshi, Director, Licensing 

and External Research, Merck & Co 

—David Kaslow, Head of Vaccines 

Project & Pipeline Leadership, Merck 

& Co 

—Ed Mascioli, Head of Orphan & 

Genetic Diseases Research Unit, Pfizer 

—Arthur Tzianabos, Vice President of 

Research, HGT Division, Shire 

—Steve Groft, Director, Office of Rare 

Diseases Research, NIH 

—Phil Ross, Managing Director, 

Healthcare, JPMorgan 

—Maarten deJong, Managing Director, 

Barclays Capital 

—Andrew Robertson, Chief Policy 

Officer, BIO Ventures for Global 

Health 

—Orin Herskowitz, Executive Director & 

Vice President, Intellectual Property 

Technology Transfer, Columbia 

Technology Ventures 

—Erik Lium, Assistant Vice Chancellor 

of Research, UCSF 

—Brian Kelly, Director, Technology, 

Enterprise & Commercialisation, Weill 

Cornell Medical College 

—Daniel Perez, Partner, Bay City Capital 

—Hubert Birner, Partner, TVM Capital 

—Glen Steinbach, COO, Johns Hopkins 

Technology Transfer 

—Markus Goebel, Managing Director, 

Novartis Venture Fund 

The Summit will strive to induce 

interactive debate, deliberation and 

discussion, networking and business 

over the 2-day period with the leaders 

in the sector. The Summit conference 

will be further enhanced by the TTS 

Initiative Business Social Network, an 

online business-networking platform 

powered by JuJaMa. The Network is a 

communication tool for business that 

will allow the posting of profiles and 

technology offers; the searching of other 

participants by category, by technology 

or licensing offer; and the setting up of 

meetings prior to, during and after the 

Summit. Total participation numbers for 

this conference will be strictly limited 

to ensure the ideal environment for real 

discussion and business. 

FOR FURTHER INFORMATION CONTACT: 

More details about the conference 

including registration information and 

the conference agenda can be found by 

contacting Tech Transfer Summit North 

America (http:// 

www.techtransfersummit.com/ 

northamerica2011). Attendees may also 

enter the Partner Code ‘‘NIH11’’ to 

register with a 10% reduction. For 

information about sign language 

interpretation or accommodation for 

disabilities, please contact Sharon 

Fields at telephone 301–594–7700 or 

fieldssh@od.nih.gov. 

Dated: August 16, 2011. 

Steven M. Ferguson, 

Deputy Director, Licensing & 

Entrepreneurship, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2011–21514 Filed 8–22–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Targeting Resistance in 

Select Gram-Negative Pathogens. 

Date: September 22–23, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Silver Spring, 8727 Colesville 

Road, Chesapeake Room, Silver Spring, MD 

20910. 

Contact Person: Nancy Lewis Ernst, PhD, 

Scientific Review Official, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–7383, 

nancy.ernst@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 17, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21512 Filed 8–22–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 76, No. 163 / Tuesday, August 23, 2011 / Notices 52671 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Partnerships for Biodefense 

(R01) 

Date: September 13, 2011. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817, 

(Telephone Conference Call) 

Contact Person: Frank S. De Silva, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–594–1009, 

fdesilva@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Partnerships for Biodefense 

(R01) 

Date: September 14, 2011. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817, 

(Telephone Conference Call) 

Contact Person: Frank S. De Silva, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–594–1009, 

fdesilva@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Application. 

Date: September 19–20, 2011. 

Time: 1 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817. 

Contact Person: Maja Maric, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

DHHS/NIH/NIAID, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892, 301–451– 

2634, maja.maric@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 17, 2011. 

Jennifer S. Spaeth, 

Director. Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21511 Filed 8–22–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; The Effect of 

Supervised Practice Driving on Driving 

Performance Among Newly Licensed Teen 

Drivers. 

Date: September 15, 2011. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call) 

Contact Person: Sathasiva B. Kandasamy, 

PhD, Scientific Review Officer, Division of 

Scientific Review, Eunice Kennedy Shriver 

National Institute of, Child Health and 

Human Development, NIH 6100 Executive 

Blvd., Room 5b01, Bethesda, MD 20892, 301– 

435–6680, skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: August 17, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21510 Filed 8–22–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Clinical Center; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the NIH 

Advisory Board for Clinical Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended to 

discuss personnel matters, the 

disclosure of which would constitute a 

clearly unwarranted invasion of privacy. 

Name of Committee: NIH Advisory Board 

for Clinical Research 

Date: October 3, 2011 

Open: 10 a.m. to 1:15 p.m. 

Agenda: To discuss intramural clinical 

research operational and funding issues. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board Room 4–2551, Bethesda, MD 20892. 

Closed: 1:15 p.m. to 2 p.m. 

Agenda: To discuss personnel matters. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board Room 4–2551, Bethesda, MD 20892. 

Contact Person: Maureen E Gormley, 

Executive Secretary, Mark O. Hatfield 

Clinical Research Center, National Institutes 

of Health, Building 10, Room 6–2551, 

Bethesda, MD 20892, (301) 496–2897. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Dated: August 17, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21509 Filed 8–22–11; 8:45 am] 

BILLING CODE 4140–01–P 

mstockstill on DSK4VPTVN1PROD with NOTICES